Raltegravir product-specific bioequivalence guidance - Scientific guideline

Scientific guidelineHumanScientific guidelines

Estonian is available via eTranslation, the European Commission's machine translation service.

Translate to Estonian | Important information about machine translation

Raltegravir product-specific bioequivalence guidance 400 mg and 600 mg film-coated tablet, 25 and 100 mg chewable tablet, 100 mg granules for oral suspension.

Keywords: Bioequivalence, generics, Raltegravir

Open consultation

Raltegravir product-specific bioequivalence guidance 400 mg and 600 mg film-coated tablet, 25 and 100 mg chewable tablet, 100 mg granules for oral suspension

Draft: consultation open Consultation dates: to Reference Number: EMA/200229/2026 Summary:

Comments should be provided using this EUSurvey form. For any technical issues, please contact the EUSurvey Support.

English (EN) (134.97 KB - PDF)

Esmakordselt avaldatud:
Vaata

Share this page